Immunomonitoring measures in relapsing-remitting multiple sclerosis

被引:11
|
作者
Matsui, M [1 ]
Araya, S
Wang, HY
Matsushima, K
Saida, T
机构
[1] Natl Utano Hosp, Ctr Neurol Dis, Clin Res Ctr, Ukyo Ku, Kyoto 6168255, Japan
[2] Natl Utano Hosp, Dept Neurol, Ukyo Ku, Kyoto 6168255, Japan
[3] Univ Tokyo, Sch Med, Dept Mol Prevent Med, Tokyo 1130033, Japan
关键词
multiple sclerosis; flow cytometry; cytokine; surface antigen;
D O I
10.1016/j.jneuroim.2003.11.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Forty-five patients with relapsing-remitting multiple sclerosis (MS) were examined to determine intracellular cytokine profiles and the surface phenotype of circulating lymphocytes during active, recovery, and stable stages. Active stage patients were characterized by decreases in CD4(+)IL-4(+) Th2 as well as CD4(+)IFN-gamma(+) Th1 cells, when compared with stable stage patients and 16 healthy controls. CCR4(+) Th2 cells were persistently decreased at every MS stage as compared to the controls. CD4(+)CD29(+) and CD4(+)CXCR3(+) cells were closely correlated with IFN-gamma-producing cells. These findings suggest that simultaneous flow cytometry for these two types of measurements can provide information concerning current immune status in MS. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:192 / 199
页数:8
相关论文
共 50 条
  • [21] Resistance Training in Relapsing-Remitting Multiple Sclerosis
    Dalgas, U.
    Kant, M.
    Stenager, E.
    [J]. AKTUELLE NEUROLOGIE, 2010, 37 (05) : 213 - 218
  • [22] Cognitive Resilience in Relapsing-Remitting Multiple Sclerosis
    Achiron, Anat
    Harel, Yermi
    Lavie, Mor
    Simon, Ely S.
    Doniger, Glen M.
    [J]. NEUROLOGY, 2010, 74 (09) : A162 - A162
  • [23] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    [J]. CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [24] PROGNOSIS OF DISABILITY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Somilo, O., V
    Kalbus, O., I
    Makarov, S. O.
    Sorokin, A. V.
    Shastun, N. P.
    [J]. WORLD OF MEDICINE AND BIOLOGY, 2023, 84 (02): : 147 - 152
  • [25] An update on cladribine for relapsing-remitting multiple sclerosis
    Holmoy, Trygve
    Torkildsen, Oivind
    Myhr, Kjell-Morten
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1627 - 1635
  • [26] Therapeutic inertia in relapsing-remitting multiple sclerosis
    Rodrigues, Rita
    Rocha, Raquel
    Bonifacio, Goncalo
    Ferro, Daniela
    Sabenca, Francisco
    Goncalves, Ana Isabel
    Correia, Filipe
    Pinheiro, Joaquim
    Loureiro, Jose Leal
    Guerreiro, Rui Pedro
    Vale, Jose
    Sa, Maria Jose
    Costa, Andreia
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 55
  • [27] A CASE OF RELAPSING-REMITTING TUMEFACTIVE MULTIPLE SCLEROSIS
    Turnbull, H.
    Karsan, N.
    Hogg, F.
    Pereira, A.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83
  • [28] Daclizumab for the treatment of relapsing-remitting multiple sclerosis
    Herwerth, Marina
    Hemmer, Bernhard
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 747 - 753
  • [29] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 457 - 457
  • [30] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797